Cardiogenic shock. Recent advances in pharmacologic management. II.
D000262:Adenylyl Cyclases / Q000378:metabolism; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D002395:Catecholamines / Q000502:physiology / Q000627:therapeutic use; D000242:Cyclic AMP / Q000096:biosynthesis / Q000378:metabolism; D003864:Depression, Chemical; D004070:Digitalis; D004071:Digitalis Glycosides / Q000627:therapeutic use; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005934:Glucagon / Q000627:therapeutic use; D005938:Glucocorticoids / Q000502:physiology; D013006:Growth Hormone / Q000502:physiology; D006801:Humans; D007328:Insulin / Q000502:physiology; D007545:Isoproterenol / Q000627:therapeutic use; D008680:Metaraminol / Q000627:therapeutic use; D008729:Methoxamine; D009203:Myocardial Infarction / Q000378:metabolism; D009638:Norepinephrine / Q000627:therapeutic use; D010042:Ouabain; D010101:Oxygen Consumption; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D010946:Plants, Medicinal; D010947:Plants, Toxic; D012770:Shock, Cardiogenic / Q000188:drug therapy* / Q000628:therapy; D013268:Stimulation, Chemical
D000305:Adrenal Cortex Hormones; D002395:Catecholamines; D004071:Digitalis Glycosides; D005230:Fatty Acids, Nonesterified; D005938:Glucocorticoids; D007328:Insulin; D010042:Ouabain; D008680:Metaraminol; D013006:Growth Hormone; D005934:Glucagon; D000242:Cyclic AMP; D010727:Phosphoric Diester Hydrolases; D000262:Adenylyl Cyclases; D008729:Methoxamine; D007545:Isoproterenol; D009638:Norepinephrine